Zimmer Holdings, Inc. (NYSE and SIX: ZMH) announced today that it has acquired the business of Cambridge, Massachusetts-based ETEX Holdings, Incorporated. The financial terms of the transaction were not disclosed. The acquisition enhances Zimmer’s Biologics portfolio of differentiated treatments through the addition of ETEX’s Beta-bsm (Injectable), CarriGen, EquivaBone (including DBM), and Gamma-bsm (Putty) bone void filler products.

“Since 1989, ETEX has been focused on Dosuk Lee’s vision of providing clinical solutions that advance the orthopaedic standard of care. His breakthrough technology in biomimetic calcium phosphate, which mimics the chemical and structural features of human bone, promotes natural bone regeneration that positively impacts patients’ lives,” said Stephen R. La Neve, ETEX president and chief executive officer. “Zimmer’s long history, dedication and focus in the orthopaedic market is a perfect complement to our technology and dramatically expands our ability to reach a broader array of clinicians.”

“Zimmer is committed to developing the most comprehensive range of biologic therapies for patients suffering from musculoskeletal joint disease, from early intervention solutions like Gel-One Cross-linked Hyaluronate and joint preservation solutions like Zimmer Knee Creations Subchondroplasty Procedure, along with Zimmer’s Chondrofix Osteochondral Allograft and Denovo NT Natural Tissue Graft personalized cartilage solutions. ETEX’s innovative bone substitute material products add more depth to a growing portfolio of solutions for the early stages of joint disease,” said Joseph A. Cucolo, president, Zimmer Americas.

Gel-One is a registered trademark of Seikagaku Corporation.

Source: Zimmer Holdings Inc., Inside INdiana Business